Katsuhiko Naoki

Katsuhiko Naoki

Auto-generated profile, based on publicly available information

Katsuhiko Naoki

Department of Respiratory Medicine Kitasato University School of Medicine Sagamihara Japan

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2008 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
HWHideo Watanabe
Hideo Watanabe
KSKenzo Soejima
Kenzo Soejima
HYHiroyuki Yasuda
Hiroyuki Yasuda
IKIchiro Kawada
Ichiro Kawada
INIchiro Nakachi
Ichiro Nakachi
AIAkitoshi Ishizaka
Akitoshi Ishizaka
Background: Alterations in the processing of the genetic information in carcinogenesis result from stable genetic mutations or epigenetic modifications. It is becoming clear that nucleosomal histones are central to proper gene expression and that aberrant DNA methylation of genes and histone methylation plays important roles in tumor progression. To date, several histone lysine methyltransferases (HKMTs) have been identified and histone lysine methylation is now considered to be a critical regulator of transcription. However, still relatively little is known about the role of HKMTs in tumorigenesis. Results: We observed differential HKMT expression in a lung cancer model in which normal human bronchial epithelial (NHBE) cells expressing telomerase, SV40 large T antigen, and Ras were immortal, formed colonies in soft agar, and expressed specific HKMTs for H3 lysine 9 and 27 residues but not for H3 lysine 4 residue. Modifications in the H3 tails affect the binding of proteins to the histone tails and regulate protein function and the position of lysine methylation marks a gene to be either activated or repressed. In the present study, suppression by siRNA of HKMTs (EZH2, G9A, SETDB1 and SUV39H1) that are over-expressed in immortalized and transformed cells lead to reduced cell proliferation and much less anchorage-independent colony growth. We also found that the suppression of H3-K9, G9A and SUV39H1 induced apoptosis and the suppression of H3-K27, EZH2 caused G1 arrest. Conclusion: Our results indicate the potential of these HKMTs in addition to the other targets for epigenetics such as DNMTs and HDACs to be interesting therapeutic targets.

11 February 2011 in International Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
KNKatsuhiko Naoki
Katsuhiko Naoki
KSKenzo Soejima
Kenzo Soejima
HOHiroaki Okamoto
Hiroaki Okamoto
JHJunko Hamamoto
Junko Hamamoto
NHNaoya Hida
Naoya Hida
KWKoshiro Watanabe
Koshiro Watanabe

1 January 2019 in Lung Cancer
Verified
Journal Article
Closed access
HHHanako Hasegawa
Hanako Hasegawa
HYHiroyuki Yasuda
Hiroyuki Yasuda
JHJunko Hamamoto
Junko Hamamoto
KMKeita Masuzawa
Keita Masuzawa
TTTetsuo Tani
Tetsuo Tani
KSKenzo Soejima
Kenzo Soejima

3 June 2021 in Cancer Research
Verified
Journal Article
Open access
PDF file
KIKota Ishioka
Kota Ishioka
HYHiroyuki Yasuda
Hiroyuki Yasuda
JHJunko Hamamoto
Junko Hamamoto
HTHideki Terai
Hideki Terai
KEKatsura Emoto
Katsura Emoto
KFKoichi Fukunaga
Koichi Fukunaga
Transdifferentiation of lung adenocarcinoma to small cell lung cancer (SCLC) has been reported in a subset of lung cancer cases that bear EGFR mutations. Several studies have reported the prerequisite role of TP53 and RB1 alterations in transdifferentiation. However, the mechanism underlying transdifferentiation remains understudied, and definitive additional events, the third hit, for transdifferentiation have not yet been identified. In addition, no prospective experiments provide direct evidence for transdifferentiation. In this study, we show that FGF9 upregulation plays an essential role in transdifferentiation. An integrative omics analysis of paired tumor samples from a patient with transdifferentiated SCLC exhibited robust upregulation of FGF9. Furthermore, FGF9 upregulation was confirmed at the protein level in four of six (66.7%) paired samples. FGF9 induction transformed mouse lung adenocarcinoma-derived cells to SCLC-like tumors in vivo through cell autonomous activation of the FGFR pathway. In vivo treatment of transdifferentiated SCLC-like tumors with the pan-FGFR inhibitor AZD4547 inhibited growth. In addition, FGF9 induced neuroendocrine differentiation, a pathologic characteristic of SCLC, in established human lung adenocarcinoma cells. Thus, the findings provide direct evidence for FGF9-mediated SCLC transdifferentiation and propose the FGF9–FGFR axis as a therapeutic target for transdifferentiated SCLC. Significance: This study demonstrates that FGF9 plays a role in the transdifferentiation of lung adenocarcinoma to small cell lung cancer.

20 June 2025 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
SMSatoru Miura
Satoru Miura
HTHiroshi Tanaka
Hiroshi Tanaka
TMToshihiro Misumi
Toshihiro Misumi
HYHiroshige Yoshioka
Hiroshige Yoshioka
TTTakaaki Tokito
Takaaki Tokito
OIon behalf of the Thoracic Oncology Research Group and all ACHILLES investigators
on behalf of the Thoracic Oncology Research Group and all ACHILLES investigators
PURPOSE: To our knowledge, the ACHILLES/TORG1834 trial is the first randomized study comparing afatinib and chemotherapy in patients with non–small cell lung cancer (NSCLC) harboring sensitizing uncommon epidermal growth factor receptor ( EGFR ) mutations. METHODS: This randomized, open-label study was performed at 51 Japanese institutions and recruited treatment-naïve patients with nonsquamous NSCLC with uncommon EGFR mutations, excluding exon 20 insertions and T790M mutations. Patients were randomly assigned 2:1 to receive afatinib (30 or 40 mg orally, at the treating physician's discretion) or a combination of platinum (cisplatin or carboplatin) and pemetrexed, followed by pemetrexed maintenance. The primary end point was progression-free survival (PFS). Secondary end points included objective response rate (ORR), overall survival, and safety. A prespecified interim analysis was planned to provide clinically meaningful information promptly, along with a crossover recommendation if necessary. RESULTS: A total of 109 patients were enrolled between March 2019 and February 2023. In the interim analysis, the Data and Safety Monitoring Committee recommended early study termination. The median PFS was significantly longer in patients receiving afatinib than in those undergoing chemotherapy (10.6 v 5.7 months; hazard ratio, 0.421 [95% CI, 0.251 to 0.706]; P = .0010). ORRs to afatinib were similar across the overall population and among participants with major uncommon (G719X, L861Q, and S768I), compound, and other mutations (61.7%, 55.8%, 72.7%, and 60.0%, respectively). The most common grade 3 or higher adverse events were diarrhea, paronychia, and rash for afatinib, and appetite loss and nausea for chemotherapy. CONCLUSION: Afatinib should be considered the standard initial therapy for patients with NSCLC with sensitizing uncommon EGFR mutations.

1 May 2018 in Lung Cancer
Verified
Journal Article
Closed access
AHAhmed E. Hegab
Ahmed E. Hegab
MOMari Ozaki
Mari Ozaki
SKShizuko Kagawa
Shizuko Kagawa
JHJunko Hamamoto
Junko Hamamoto
HYHiroyuki Yasuda
Hiroyuki Yasuda
TBTomoko Betsuyaku
Tomoko Betsuyaku